Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | PLAT | P00750 | 1/20 | 0.39 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.36 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.36 |
| ▸ | CPN1 | P15169 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1694358 | 1.00 | ITGB3 (0.43) | ITGB3ITGA2BCYP2D6LMNAPLG | |
| SCHEMBL1694214 | 1.00 | ITGB3 (0.43) | ITGB3ITGA2BCYP2D6LMNAPLG | |
| Tert-Butanol SCHEMBL28555468 | 0.92 | ITGB3 (0.39) | ITGB3ITGA2BCYP2D6LMNAPLG | |
| SCHEMBL3155411 | 0.88 | PLG (0.42) | CYP2D6LMNAPLGPLATCHRM2 | |
| SCHEMBL790440 | 0.88 | PLG (0.42) | CYP2D6LMNAPLGPLATCHRM2 | |
| SCHEMBL2337249 | 0.88 | PLG (0.42) | CYP2D6LMNAPLGPLATCHRM2 | |
| Hydrochloric Acid SCHEMBL25248778 | 0.86 | PLG (0.41) | CYP2D6LMNAPLGPLATCHRM2 | |
| Hydrochloric Acid SCHEMBL25287438 | 0.86 | PLG (0.41) | CYP2D6LMNAPLGPLATCHRM2 | |
| SCHEMBL1935334 | 0.85 | ITGB3 (0.44) | ITGB3ITGA2BLMNACHRM2CHRM1 | |
| SCHEMBL30440562 | 0.85 | CHRM3 (0.46) | ITGB3ITGA2BCYP2D6LMNAPLG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199583-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2024-06-20 | — | — | US | disclosed |
| US-11926617-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2024-03-12 | — | — | US | disclosed |
| CN-117580830-A | Novel pyridine-sulfonamide derivatives as sigma ligands | 塔拉森调理公司 | 2024-02-20 | — | — | CN | disclosed |
| WO-2023244918-A1 | QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023240038-A1 | TRICYCLIC QUINOLONE BCL6 BIFUNCTIONAL DEGRADERS | Treeline Biosciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| EP-3340983-B1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | SOUTHERN RESEARCH INSTITUTE (US) | 2023-06-08 | — | — | US | disclosed |
| US-11014921-B2 | Therapeutic compounds and methods of use thereof | REGENTS OF THE UNIVERSITY OF MINNESOTA (US) | 2021-05-25 | — | — | US | disclosed |
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | JANSSEN PHARMACEUTICA NV (BE) | 2021-04-22 | — | — | US | disclosed |
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-08-20 | — | — | US | disclosed |
| US-5677448-A | CHEMICAL INTERMEDIATES FOR MAKING ANTAGONIST OF THROMBIN, TREATING THROMBOSIS, STROKE, INFLAMMATION, ARTERIOSCLEROSIS, CARDIOVASCULAR DISORDERS | HOFFMANN-LA ROCHE INC. (US) | 1997-10-14 | — | — | US | disclosed |
| US-5595999-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-01-21 | — | — | US | disclosed |
| US-5583146-A | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-10 | — | — | US | disclosed |
| US-5583133-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-12-10 | — | — | US | disclosed |
| US-5578594-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1996-11-26 | — | — | US | disclosed |
| US-5532232-A | INHIBIT THROMBIN INDUCED PLATELET AGGREGATION; FIBRINOGEN ANTICOAGULANTS IN BLOOD | HOFFMANN-LA ROCHE INC. (US) | 1996-07-02 | — | — | US | disclosed |
| EP-0648780-A1 | Heterocyclic thrombin inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-04-19 | — | — | EP | disclosed |
| US-5405854-A | Anticoagulants | HOFFMANN-LA ROCHE INC. (US) | 1995-04-11 | — | — | US | disclosed |
| US-5393760-A | Cardiovascular disorders, antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1995-02-28 | — | — | US | disclosed |
| US-5260307-A | Inhibit thrombin-induced platlet aggregation and clotting of fibrogen in plasma | HOFMANN-LA ROCHE INC. (US) | 1993-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115040-A1 | OGA INHIBITOR COMPOUNDS | OGA, OGT, GRN | ITGB3 3600/4885ITGA2B 3193/4885CYP2D6 4092/4885 |
| US-20200262818-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | ITGB3 680/4885ITGA2B 479/4885CYP2D6 756/4885 |
| US-11014921-B2 | Therapeutic compounds and methods of use thereof | CD47, C3AR1, HLA-DRB1 | ITGB3 1336/4885ITGA2B 2779/4885CYP2D6 1486/4885 |
| US-20240199583-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF IMMUNE AND INFLAMMATORY DISORDERS | CFD, TFPI, CFH | ITGB3 680/4885ITGA2B 479/4885CYP2D6 756/4885 |
| US-20230172932-A1 | SUBSTITUTED QUINAZOLINE SULFONAMIDES AS THIOREDOXIN INTERACTING PROTEIN (TXNIP) INHIBITORS | TXN, TXNL1, TXN2 | ITGB3 4834/4885ITGA2B 4872/4885CYP2D6 2977/4885 |
| US-11926617-B2 | Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders | CFD, TFPI, CFH | ITGB3 680/4885ITGA2B 479/4885CYP2D6 756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.